冻干粉 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-07. Numbers and descriptions here follow the published literature rather than marketing material.
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| 性质 | 取值 | 备注 |
|---|---|---|
| 外观 | 白色至类白色冻干粉 | 常见形态 |
| 溶解性 | 易溶于水与水性缓冲液 | 多肽类通性 |
| 典型储存温度 | -20°C 或更低 | 干燥避光 |
| 常用纯度方法 | 反相高效液相色谱 | 214 nm 紫外检测 |
| 常用分子量确认 | 质谱 | 电喷雾或激光解吸 |
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
at the top. Each layer of fluid moves faster than the one just below it, and friction between them gives rise to a force resisting their relative motion. In particular, the fluid applies on the top plate a force in the direction opposite to its motion, and an equal but opposite force on the bottom plate. An external force is therefore required in order to keep the top plate moving at constant speed. In many fluids, the flow velocity is observed to vary linearly from zero at the bottom to
Rossman (1993), judge on the United States Court of Appeals for the Tenth Circuit Nancy Abudu (1996), lawyer and nominee to the United States Court of Appeals for the Eleventh Circuit Nusrat Jahan Choudhury (1998), lawyer and nominee to the United States District Court for the Eastern District of New York Roy Altman (2004), judge of the United States District Court for the Southern District of Florida Raph Graybill (2010), attorney, chief legal counsel to Steve Bullock and Democratic candidate in the 2020 Montana Attorney General election Shana Knizhnik (2010), lawyer and author known for her book Notorious R.B.G.: The Life and Times of Ruth Bader Ginsburg
MedPlus was founded in 2006 by Madhukar Gangadi. The company's first store was launched in Hyderabad. Initially operating under the Aushadhi brand name, it was rebranded as MedPlus after the opening of the first 48 stores. The company opened pharmacies in the western states of Gujarat and Rajasthan in 2007 but had to shut down and exit operations due to recurring losses. It relaunched stores in Ahmedabad, Gujarat in 2014. In 2008, it opened diagnostics centers in five cities under its subsidiary MedPlus Pathlabs. In 2015, it started its e-pharmacy division. In December 2021, MedPlus Health Services launched its initial public offering (IPO) and got listed on the Indian stock exchanges.
Sources: en.wikipedia.org
The condition, or types of it, has had various other names over the years and in different nations; "osteogenesis imperfecta" has, however, been the most widely accepted name for the condition since the late 20th century. Among some of the most common alternatives are "fragilitas ossium"; "Ekman–Lobstein syndrome", and "Vrolik syndrome", both eponyms; and, the colloquialism, "brittle bone disease".
Some of this pool of 238Pu was used in a multi-mission radioisotope thermoelectric generator (MMRTG) for the 2020 Mars Rover mission and two additional MMRTGs for a notional 2024 NASA mission. 21 kg (46 lb) would remain after that, including approximately 4 kg (8.8 lb) just barely meeting the NASA specification. Since isotope content in the material is lost over time to radioactive decay while in storage, this stock could be brought up to NASA specifications by blending it with a smaller amount of freshly produced 238Pu with a higher content of the isotope, and therefore energy density.
=== Shelf-life extension === Shelf-life extension results from low processing temperatures in conjunction with rapid transition of water through sublimation. With these processing conditions, deterioration reactions, including nonenzymic browning, enzymatic browning, and protein denaturation, are minimized. When the product is successfully dried, packaged properly, and placed in ideal storage conditions the foods have a shelf life of greater than 12 months.
Bacteria synthesize pantothenic acid from the amino acids aspartate and a precursor to the amino acid valine. Aspartate is converted to β-alanine. The amino group of valine is replaced by a keto-moiety to yield α-ketoisovalerate, which, in turn, forms α-ketopantoate following transfer of a methyl group, then D-pantoate (also known as pantoic acid) following reduction. β-alanine and pantoic acid are then condensed to form pantothenic acid (see figure).
Sources: en.wikipedia.org
Grifols began in 1909 when hematologist and scientist Josep Antoni Grífols i Roig founded a clinical analysis laboratory in Barcelona: the Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos, a precursor to Laboratorios Grifols. In Spain, Grífols i Roig patented the first instrument for carrying out indirect blood transfusions, the transfusion flebula. Post-war, Grífols i Roig and his sons, Josep Antoni Grífols i Lucas, a hematologist, and Víctor Grífols i Lucas, a chemist and pharmacist, founded Laboratorios Grifols, which began the start of the business dedicated to clinical analysis and the preparation of freeze-dried plasma. In 1952, for the first time, the results of a systematic application of the plasmapheresis technique in humans was published in the British Medical Journal thanks to a study led by Josep Antoni Grífols i Lucas. Control of the company was handed down to Víctor Grifols Roura in 1987, when Grifols created the holding company Grupo Grifols. This unified the commercial company with its clinical diagnostic, plasma-derived medicines and parenteral operations. From there, in 1988 Grifols opened its first subsidiary, in Portugal, marking the beginning of the company’s international expansion.
A research study in which the medical records of groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke and those who do not smoke) are compared for a particular outcome. Also called a retrospective cohort study. (NCI) Historical control subject
A 100-gram reference quantity of raw soybeans supplies 1,866 kilojoules (446 kilocalories) of food energy and are 9% water, 30% carbohydrates, 20% total fat and 36% protein. Peanuts are the only legumes with a higher fat content (48%) and calorie count (2,385 kJ). They contain less carbohydrates (21%), protein (25%) and dietary fiber (9%). Soybeans are a rich source of essential nutrients, providing in a 100-gram serving (raw, for reference) high contents of the Daily Value (DV) especially for protein (36% DV), dietary fiber (37%), iron (121%), manganese (120%), phosphorus (101%) and several B vitamins, including folate (94%) (table). High contents also exist for vitamin K, magnesium, zinc and potassium. For human consumption, soybeans must be processed prior to consumption–either by cooking, roasting, or fermenting–to destroy the trypsin inhibitors (serine protease inhibitors). Raw soybeans, including the immature green form, are toxic to all monogastric animals.
Sources: en.wikipedia.org
多肽在反相柱上按疏水性差异分离，能有效区分主峰、缺失序列片段与氧化产物。配合紫外检测可获得可量化的纯度百分比，是肽类分析的常规手段。
一般建议密封、避光、干燥，并在 -20°C 或更低温度下存放。温度波动和湿气是主要风险，长期存放应避免反复开启容器。
没有统一答案，取决于缓冲液、浓度、pH 与储存温度。多数做法是冷藏并在数天至数周内用完，具体期限需要通过稳定性实验确认。
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.